Vr Adviser, LLC Travere Therapeutics, Inc. Transaction History

Vr Adviser, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $20 Million - $45.3 Million	2,623,677 New	2,623,677 $23.5 Million
Q2 2022 May 15, 2023	BUY	$20.94 - $30.01 $35.8 Million - $51.4 Million	1,711,102 New	1,711,102 $41.5 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $5.94 Million - $8.52 Million	-283,895 Reduced 14.23%	1,711,102 $41.5 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $6.39 Million - $8.18 Million	262,587 Added 15.16%	1,994,997 $61.9 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $22.5 Million - $43.4 Million	1,732,410 New	1,732,410 $42 Million

214

94.3M

1.2M

778K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.32B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

Stay updated on Vr Adviser, LLC with notifications on news.